Risco de erupção cutânea em pacientes oncológicos tratados com inibidores da PD-1/PD-L1: Uma revisão sistemática atualizada e metanálise
DermatologiaResumo original em inglês
O que aconteceu
This study was designed to assess the risk of programmed cell death-1 (PD-1) or programmed cell death ligand 1 (PD-L1) related rash in various situations.
Guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses, data on rash in clinical trials related to PD-1 or PD-L1 were collected to comprehensively evaluate its incidence risk in various situations.
O que encontraram
Ninety-five clinical trials, divided into 12 groups according to treatment regimens, were enrolled for the final comprehensive assessments and analyses. Compared with chemotherapy or placebo alone, both PD-1 and PD-L1 inhibitors increased the risk of developing rashes for all grades (odds ratio [OR] = 1.61, P = .0003; OR = 2.94, P < .00001). Whether used in combination with chemotherapy or other types of immunosuppressants, similar risk trends were observed (OR = 2.42, P < .00001; OR = 2.11, P = .0007; OR = 4.49, P < .00001; OR = 5.15, P = .0006; OR = 3.16, P = .0002).
Por que isso importa
Both PD-1 and PD-L1 increased the risk of rash occurrence, especially when used in combination with other immunosuppressive antitumor drugs.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis
Qunqun Jiang, Junru Liu, Zhuoqi Li, Chi Zhang, Qi Dang, Yuan Tian
Descritores MeSH
- Immune Checkpoint Inhibitors
- Exanthema
- Neoplasms
- B7-H1 Antigen
- Programmed Cell Death 1 Receptor
- Humans
Veja também
Estudos relacionados
- Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis
- Efficacy of PD-1/PD-L1 and LAG-3 immune checkpoint inhibitors in the treatment of patients with solid tumor
- Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors in malignant solid tumors: a meta-analysis and network meta-analysis
- Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines